Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phthalimide class. It is known by the code name ML026 and has been studied primarily as an experimental ligand in structural biology and biochemical research. The molecule has been co-crystallized with AmpC beta-lactamase to study enzyme inhibition mechanisms but is not approved for clinical use or marketed as a pharmaceutical drug. Its mechanism of action involves binding to bacterial beta-lactamase enzymes; however, it is not developed or approved for therapeutic applications[6][8][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[(1R)-1-carboxy-2-naphthalen-1-ylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid.